Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,557.36
(
-0.36%
)
US TECH 100
23,362.80
(
-0.67%
)
Dow Jones
46,162.22
(
-0.10%
)
Brent Oil
100.91
(
4.25%
)
Bitcoin
69,175.00
(
-2.43%
)
News Focus
News Focus
Post# of 257275
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 242414

Friday, 06/16/2023 3:30:27 PM

Friday, June 16, 2023 3:30:27 PM

Post# of 257275
LLY fails_to_show Emgality superiority_to PFE’s Nurtec in_phase-4_trial in prevention of episodic migraine:

https://finance.yahoo.com/news/first-kind-head-head-clinical-160000632.html

https://finance.yahoo.com/news/1-eli-lillys-migraine-drug-162030131.html

This trial was a calculated gamble by LLY to slow down the commercial uptake of PFE’s Nurtec, which has been outselling Emgality despite Nurtec’s coming to market later.

p.s. Between Nurtec and Zavzpret, PFE forecasts peak annual migraine sales of $6B (#msg-171411588).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today